Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-12-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Online Access: | https://doi.org/10.1007/s00262-024-03873-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571663394275328 |
|---|---|
| author | Emiel A. De Jaeghere Sandra Tuyaerts An M. T. Van Nufel Ann Belmans Kris Bogaerts Regina Baiden-Amissah Lien Lippens Peter Vuylsteke Stéphanie Henry Xuan Bich Trinh Peter A. van Dam Sandrine Aspeslagh Alex De Caluwé Eline Naert Diether Lambrechts An Hendrix Olivier De Wever Koen K. Van de Vijver Frédéric Amant Katrien Vandecasteele Hannelore G. Denys |
| author_facet | Emiel A. De Jaeghere Sandra Tuyaerts An M. T. Van Nufel Ann Belmans Kris Bogaerts Regina Baiden-Amissah Lien Lippens Peter Vuylsteke Stéphanie Henry Xuan Bich Trinh Peter A. van Dam Sandrine Aspeslagh Alex De Caluwé Eline Naert Diether Lambrechts An Hendrix Olivier De Wever Koen K. Van de Vijver Frédéric Amant Katrien Vandecasteele Hannelore G. Denys |
| author_sort | Emiel A. De Jaeghere |
| collection | DOAJ |
| format | Article |
| id | doaj-art-7a2dbda2ca4c4bf0a6184c73b5f2570b |
| institution | Kabale University |
| issn | 1432-0851 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Springer |
| record_format | Article |
| series | Cancer Immunology, Immunotherapy |
| spelling | doaj-art-7a2dbda2ca4c4bf0a6184c73b5f2570b2025-02-02T12:26:31ZengSpringerCancer Immunology, Immunotherapy1432-08512024-12-017411410.1007/s00262-024-03873-5Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO studyEmiel A. De Jaeghere0Sandra Tuyaerts1An M. T. Van Nufel2Ann Belmans3Kris Bogaerts4Regina Baiden-Amissah5Lien Lippens6Peter Vuylsteke7Stéphanie Henry8Xuan Bich Trinh9Peter A. van Dam10Sandrine Aspeslagh11Alex De Caluwé12Eline Naert13Diether Lambrechts14An Hendrix15Olivier De Wever16Koen K. Van de Vijver17Frédéric Amant18Katrien Vandecasteele19Hannelore G. Denys20Department of Medical Oncology (Route 535), Ghent University HospitalGynaecologic Oncology, Department of Oncology, KU LeuvenAnticancer Fund (ACF)Biostatistics and Statistical Bioinformatics Centre (L-BioStat), KU LeuvenBiostatistics and Statistical Bioinformatics Centre (L-BioStat), KU LeuvenGynaecologic Oncology, Department of Oncology, KU LeuvenCancer Research Institute Ghent (CRIG)Department of Hemato-Oncology, Centre Hospitalier Universitaire Université Catholique de Louvain Namur (Sainte-Elisabeth)Department of Hemato-Oncology, Centre Hospitalier Universitaire Université Catholique de Louvain Namur (Sainte-Elisabeth)Department of Gynecologic Oncology and Senology, University Hospital AntwerpDepartment of Gynecologic Oncology and Senology, University Hospital AntwerpDepartment of Medical Oncology, University Hospital BrusselsDepartment of Radiation Oncology, Jules Bordet InstituteDepartment of Medical Oncology (Route 535), Ghent University HospitalVIB–KU Louvain Center for Cancer BiologyCancer Research Institute Ghent (CRIG)Cancer Research Institute Ghent (CRIG)Cancer Research Institute Ghent (CRIG)Gynaecologic Oncology, Department of Oncology, KU LeuvenCancer Research Institute Ghent (CRIG)Department of Medical Oncology (Route 535), Ghent University Hospitalhttps://doi.org/10.1007/s00262-024-03873-5 |
| spellingShingle | Emiel A. De Jaeghere Sandra Tuyaerts An M. T. Van Nufel Ann Belmans Kris Bogaerts Regina Baiden-Amissah Lien Lippens Peter Vuylsteke Stéphanie Henry Xuan Bich Trinh Peter A. van Dam Sandrine Aspeslagh Alex De Caluwé Eline Naert Diether Lambrechts An Hendrix Olivier De Wever Koen K. Van de Vijver Frédéric Amant Katrien Vandecasteele Hannelore G. Denys Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study Cancer Immunology, Immunotherapy |
| title | Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study |
| title_full | Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study |
| title_fullStr | Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study |
| title_full_unstemmed | Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study |
| title_short | Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study |
| title_sort | correction pembrolizumab radiotherapy and an immunomodulatory five drug cocktail in pretreated patients with persistent recurrent or metastatic cervical or endometrial carcinoma results of the phase ii primmo study |
| url | https://doi.org/10.1007/s00262-024-03873-5 |
| work_keys_str_mv | AT emieladejaeghere correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT sandratuyaerts correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT anmtvannufel correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT annbelmans correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT krisbogaerts correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT reginabaidenamissah correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT lienlippens correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT petervuylsteke correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT stephaniehenry correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT xuanbichtrinh correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT peteravandam correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT sandrineaspeslagh correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT alexdecaluwe correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT elinenaert correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT dietherlambrechts correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT anhendrix correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT olivierdewever correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT koenkvandevijver correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT fredericamant correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT katrienvandecasteele correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy AT hanneloregdenys correctionpembrolizumabradiotherapyandanimmunomodulatoryfivedrugcocktailinpretreatedpatientswithpersistentrecurrentormetastaticcervicalorendometrialcarcinomaresultsofthephaseiiprimmostudy |